Although both the SCS2 subtype and SCS4 subtype showed high enrichment of goblet cell markers such as TFF3 and MUC2 after adjusting of tumor purity data (Fig. S5), only the PCA score of subtype 2 goblet cell signature and the SCS2 subtype were linked with worse clinical behavior and enrichment levels of stromal cell‐ and stromal pathway‐related signatures. The gene discussed is MUC2; the disease is neoplasm.